Influenza B strain confirmed
FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...
You may also be interested in...
Reverse genetics holds the greatest promise for developing cell culture-based vaccines, FDA's Vaccines & Related Biological Products Advisory Committee said Feb. 19
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.